AKT1 mutations are seen in about 1% of all tumors, and in about 3% of skin cancers, 3% of breast cancers, 1% of colorectal cancers, and 0.5% of lung cancers. A recurrent mutation, E17K is also seen in breast, lung and colorectal cancer and may indicate sensitivity to AKT inhibitors based on preclinical studies. AKT mutations in colorectal carcinoma may also indicate a resistance to EGFR inhibitors based on a clinical study.